Samuel Padovani Steffen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Samuel Padovani Steffen has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Fabio Antonio Gaiotto
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Unidade de Transplante, Departamento de Cirurgia Cardiovascular
5 shared publications - Alvaro Perazzo
Universidade de São Paulo
4 shared publications - Fabiana Goulart Marcondes Braga
Universidade de São Paulo
3 shared publications - Gabriel Barros Aulicino
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Brasil
3 shared publications - Mônica Samuel Avila
Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade Medicina, Universidade de Sao Paulo, Brazil
3 shared publications - Arina Peixoto Nobre
Universidade de Fortaleza, Brasil
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 6
Mudança dos Padrões da Mortalidade Fora do Hospital e da Perda Prematura de Vida em Cardiomiopatias: Um Estudo Nacional Baseado em População
Fundamento: As cardiomiopatias são uma importante causa de mortalidade cardiovascular, apresentando fenótipos dependentes da idade que variam desde morte súbita cardíaca (MSC) até insuficiência cardíaca progressiva. Apesar da queda nas taxas de mortalidade, lacunas na prevenção e no acesso a terapias avançadas podem se manifestar como mudanças no local do óbito e persistência de mortalidade prematura. Objetivos: Avaliar tendências temporais da mortalidade relacionada às cardiomiopatias no Brasil, examinar padrões etários no local do óbito e quantificar a mortalidade prematura por meio dos anos de vida perdidos (AVP). Métodos: Este estudo ecológico nacional, baseado em população, analisou 369 570 óbitos no Brasil (1996–2024) em que a cardiomiopatia (CID-10 I42) foi a causa básica. Tendências temporais foram avaliadas por regressão de Poisson, e associações entre idade e local do óbito foram estimadas por razões de chances (OR). Os AVP foram calculados utilizando tábuas de vida nacionais. Resultados: A mortalidade ajustada por idade diminuiu 1,7% ao ano (p<0,001). Óbitos hospitalares caíram de 75% para 43%, enquanto óbitos domiciliares aumentaram de 20% para 38%, com ponto de inflexão significativo por volta de 2011. Óbitos em vias públicas, usados como proxy de MSC, foram mais frequentes entre adultos de 20–39 anos (4,8%) do que entre aqueles com ≥60 anos (0,8%; OR 2,88; IC 95% 2,68–3,10). O total de AVP atingiu 6,83 milhões de anos. Indivíduos de 20–39 anos representaram apenas 5,5% dos óbitos, mas contribuíram com 12,8% dos AVP totais, com média de 42,9 anos perdidos por óbito. Conclusões: Apesar da queda na mortalidade, óbitos fora do ambiente hospitalar tornaram-se mais frequentes. O excesso de AVP entre adultos jovens evidencia lacunas na prevenção da MSC. Estratégias específicas por faixa etária são necessárias para reduzir a mortalidade prematura.
- 29 September 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 6
Open AccessMudança dos Padrões da Mortalidade Fora do Hospital e da Perda Prematura de Vida em Cardiomiopatias: Um Estudo Nacional Baseado em População
Fundamento: As cardiomiopatias são uma importante causa de mortalidade cardiovascular, apresentando fenótipos dependentes da idade que variam desde morte súbita cardíaca (MSC) até insuficiência cardíaca progressiva. Apesar da queda nas taxas de mortalidade, lacunas na prevenção e no acesso a terapias avançadas podem se manifestar como mudanças no local do óbito e persistência de mortalidade prematura. Objetivos: Avaliar tendências temporais da mortalidade relacionada às cardiomiopatias no Brasil, examinar padrões etários no local do óbito e quantificar a mortalidade prematura por meio dos anos de vida perdidos (AVP). Métodos: Este estudo ecológico nacional, baseado em população, analisou 369 570 óbitos no Brasil (1996–2024) em que a cardiomiopatia (CID-10 I42) foi a causa básica. Tendências temporais foram avaliadas por regressão de Poisson, e associações entre idade e local do óbito foram estimadas por razões de chances (OR). Os AVP foram calculados utilizando tábuas de vida nacionais. Resultados: A mortalidade ajustada por idade diminuiu 1,7% ao ano (p<0,001). Óbitos hospitalares caíram de 75% para 43%, enquanto óbitos domiciliares aumentaram de 20% para 38%, com ponto de inflexão significativo por volta de 2011. Óbitos em vias públicas, usados como proxy de MSC, foram mais frequentes entre adultos de 20–39 anos (4,8%) do que entre aqueles com ≥60 anos (0,8%; OR 2,88; IC 95% 2,68–3,10). O total de AVP atingiu 6,83 milhões de anos. Indivíduos de 20–39 anos representaram apenas 5,5% dos óbitos, mas contribuíram com 12,8% dos AVP totais, com média de 42,9 anos perdidos por óbito. Conclusões: Apesar da queda na mortalidade, óbitos fora do ambiente hospitalar tornaram-se mais frequentes. O excesso de AVP entre adultos jovens evidencia lacunas na prevenção da MSC. Estratégias específicas por faixa etária são necessárias para reduzir a mortalidade prematura.
- Open Access
- 29 September 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 6
Shifting Patterns of Out-Of-Hospital Mortality and Premature Life Loss in Cardiomyopathies: A Nationwide Population-Based Study
Background: Cardiomyopathies are a major cause of cardiovascular mortality, presenting age-dependent phenotypes ranging from sudden cardiac death (SCD) to progressive heart failure. Despite declining mortality rates, gaps in prevention and access to advanced therapies may manifest as shifts in the place of death and persistent premature mortality. Objectives: To evaluate temporal trends in cardiomyopathy-related mortality in Brazil, assess age-related patterns in the place of death, and quantify premature mortality through years of life lost (YLL). Methods: This nationwide, population-based [...] Abstract Background: Cardiomyopathies are a major cause of cardiovascular mortality, presenting age-dependent phenotypes ranging from sudden cardiac death (SCD) to progressive heart failure. Despite declining mortality rates, gaps in prevention and access to advanced therapies may manifest as shifts in the place of death and persistent premature mortality. Objectives: To evaluate temporal trends in cardiomyopathy-related mortality in Brazil, assess age-related patterns in the place of death, and quantify premature mortality through years of life lost (YLL). Methods: This nationwide, population-based
- 29 September 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 6
Open AccessShifting Patterns of Out-Of-Hospital Mortality and Premature Life Loss in Cardiomyopathies: A Nationwide Population-Based Study
Background: Cardiomyopathies are a major cause of cardiovascular mortality, presenting age-dependent phenotypes ranging from sudden cardiac death (SCD) to progressive heart failure. Despite declining mortality rates, gaps in prevention and access to advanced therapies may manifest as shifts in the place of death and persistent premature mortality. Objectives: To evaluate temporal trends in cardiomyopathy-related mortality in Brazil, assess age-related patterns in the place of death, and quantify premature mortality through years of life lost (YLL). Methods: This nationwide, population-based [...] Abstract Background: Cardiomyopathies are a major cause of cardiovascular mortality, presenting age-dependent phenotypes ranging from sudden cardiac death (SCD) to progressive heart failure. Despite declining mortality rates, gaps in prevention and access to advanced therapies may manifest as shifts in the place of death and persistent premature mortality. Objectives: To evaluate temporal trends in cardiomyopathy-related mortality in Brazil, assess age-related patterns in the place of death, and quantify premature mortality through years of life lost (YLL). Methods: This nationwide, population-based
- Open Access
- 22 April 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eRW1353
Perioperative management of adult patients undergoing coronary artery bypass grafting and valve surgery: a literature review
Purpose of review Coronary artery bypass grafting, revascularization by percutaneous coronary intervention, and heart valve surgery are crucial therapeutic interventions for patients with various cardiovascular diseases. The objective of this literature review was to present the main evidence and practical aspects of the perioperative management of patients undergoing coronary artery bypass grafting and heart valve surgery. Recent findings Despite advancements in surgical and anesthetic techniques, coronary artery bypass grafting and heart valve surgery present significant risks for perioperative complications
- 22 April 2025
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 23, eRW1353
Open AccessPerioperative management of adult patients undergoing coronary artery bypass grafting and valve surgery: a literature review
Purpose of review Coronary artery bypass grafting, revascularization by percutaneous coronary intervention, and heart valve surgery are crucial therapeutic interventions for patients with various cardiovascular diseases. The objective of this literature review was to present the main evidence and practical aspects of the perioperative management of patients undergoing coronary artery bypass grafting and heart valve surgery. Recent findings Despite advancements in surgical and anesthetic techniques, coronary artery bypass grafting and heart valve surgery present significant risks for perioperative complications
- Open Access
Gene expression analysis of primary graft dysfunction in adult heart transplant recipients: A cohort study
- Open Access
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (10)
Cardiac Sarcoidosis Reactivation in a Transplanted Heart: An Unusual Case of New Graft Dysfunction
Introduction Cardiac sarcoidosis (CS) is an uncommon yet potentially life-threatening manifestation of systemic sarcoidosis. Recurrence of CS following heart transplantation (HTx) is an exceedingly rare event and presents a significant diagnostic challenge. […] Cardiac Sarcoidosis Reactivation in a Transplanted Heart: An Unusual Case of New Graft Dysfunction Introduction Cardiac sarcoidosis (CS) is an uncommon yet potentially life-threatening manifestation of systemic sarcoidosis. Recurrence of CS following heart transplantation (HTx) is an exceedingly rare event and presents a significant diagnostic challenge. […] Cardiac Sarcoidosis Reactivation in a Transplanted Heart: An Unusual Case of New Graft Dysfunction
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (10)
Open AccessCardiac Sarcoidosis Reactivation in a Transplanted Heart: An Unusual Case of New Graft Dysfunction
Introduction Cardiac sarcoidosis (CS) is an uncommon yet potentially life-threatening manifestation of systemic sarcoidosis. Recurrence of CS following heart transplantation (HTx) is an exceedingly rare event and presents a significant diagnostic challenge. […] Cardiac Sarcoidosis Reactivation in a Transplanted Heart: An Unusual Case of New Graft Dysfunction Introduction Cardiac sarcoidosis (CS) is an uncommon yet potentially life-threatening manifestation of systemic sarcoidosis. Recurrence of CS following heart transplantation (HTx) is an exceedingly rare event and presents a significant diagnostic challenge. […] Cardiac Sarcoidosis Reactivation in a Transplanted Heart: An Unusual Case of New Graft Dysfunction
- Open Access
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (10) , e20250311
Reativação da Sarcoidose Cardíaca em um Coração Transplantado: Um Caso Incomum de Nova Disfunção do Enxerto
Introdução A sarcoidose cardíaca (SC) é uma manifestação incomum, porém potencialmente fatal, da sarcoidose sistêmica. A recorrência da SC após transplante cardíaco (TC) é um evento extremamente raro e representa um desafio diagnóstico significativo. […] Reativação da Sarcoidose Cardíaca em um Coração Transplantado: Um Caso Incomum de Nova Disfunção do Enxerto Introdução A sarcoidose cardíaca (SC) é uma manifestação incomum, porém potencialmente fatal, da sarcoidose sistêmica. A recorrência da SC após transplante cardíaco (TC) é um evento extremamente raro e representa um desafio diagnóstico significativo. […] Reativação da Sarcoidose Cardíaca em um Coração Transplantado: Um Caso Incomum de Nova Disfunção do Enxerto
- 1 January 2025
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 122 (10) , e20250311
Open AccessReativação da Sarcoidose Cardíaca em um Coração Transplantado: Um Caso Incomum de Nova Disfunção do Enxerto
Introdução A sarcoidose cardíaca (SC) é uma manifestação incomum, porém potencialmente fatal, da sarcoidose sistêmica. A recorrência da SC após transplante cardíaco (TC) é um evento extremamente raro e representa um desafio diagnóstico significativo. […] Reativação da Sarcoidose Cardíaca em um Coração Transplantado: Um Caso Incomum de Nova Disfunção do Enxerto Introdução A sarcoidose cardíaca (SC) é uma manifestação incomum, porém potencialmente fatal, da sarcoidose sistêmica. A recorrência da SC após transplante cardíaco (TC) é um evento extremamente raro e representa um desafio diagnóstico significativo. […] Reativação da Sarcoidose Cardíaca em um Coração Transplantado: Um Caso Incomum de Nova Disfunção do Enxerto
- Open Access
- 1 January 2025
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 40 (6)
History and Application of Mechanical Assist Devices as a Bridge to Heart Transplant: A Review and Perspectives in Brazil
Mechanical circulatory support (MCS) devices have evolved significantly over the past decades and play a vital role in managing end-stage heart failure, especially as a bridge to heart transplantation. From the pioneering heart-lung machines to third-generation ventricular assist devices (VADs), MCS technology has advanced to provide more durable, efficient, and safer options for both shortand long-term support. This review outlines the historical development of mechanical assist devices, the types of available supports - ranging from intra-aortic balloon pumps and extracorporeal membrane oxygenation to implantable devices like HeartMate 3 - and their clinical indications and complications. Special attention is given to right ventricular dysfunction, thromboembolic and hemorrhagic complications, and infections, which remain major challenges in the management of patients with MCS devices.In Brazil, despite the growing evidence supporting MCS in critically ill patients, access remains limited due to financial and systemic constraints. The review explores the current landscape of device availability in the country, national guidelines, cost-effectiveness data, and the impact of recent changes in transplant allocation criteria that prioritize patients receiving mechanical support. Notably, the approval of long-term VADs for destination therapy in the public health system in 2024 marks a significant milestone.This review offers a comprehensive perspective on MCS utilization, highlighting both global advances and Brazil-specific challenges. By identifying gaps in access and proposing future directions, it advocates for expanded use of these life-saving technologies to improve survival and quality of life in advanced heart failure patients.
- 1 January 2025
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 40 (6)
Open AccessHistory and Application of Mechanical Assist Devices as a Bridge to Heart Transplant: A Review and Perspectives in Brazil
Mechanical circulatory support (MCS) devices have evolved significantly over the past decades and play a vital role in managing end-stage heart failure, especially as a bridge to heart transplantation. From the pioneering heart-lung machines to third-generation ventricular assist devices (VADs), MCS technology has advanced to provide more durable, efficient, and safer options for both shortand long-term support. This review outlines the historical development of mechanical assist devices, the types of available supports - ranging from intra-aortic balloon pumps and extracorporeal membrane oxygenation to implantable devices like HeartMate 3 - and their clinical indications and complications. Special attention is given to right ventricular dysfunction, thromboembolic and hemorrhagic complications, and infections, which remain major challenges in the management of patients with MCS devices.In Brazil, despite the growing evidence supporting MCS in critically ill patients, access remains limited due to financial and systemic constraints. The review explores the current landscape of device availability in the country, national guidelines, cost-effectiveness data, and the impact of recent changes in transplant allocation criteria that prioritize patients receiving mechanical support. Notably, the approval of long-term VADs for destination therapy in the public health system in 2024 marks a significant milestone.This review offers a comprehensive perspective on MCS utilization, highlighting both global advances and Brazil-specific challenges. By identifying gaps in access and proposing future directions, it advocates for expanded use of these life-saving technologies to improve survival and quality of life in advanced heart failure patients.
- 17 August 2023
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 3 (1)
Surgical Treatment of Cardiomyopathy
Ischemic Cardiomyopathy Ischemic heart disease is the most common cause, and at the same time, it is the main isolated risk factor that favors the increased incidence of heart failure in the world. Several improvements incorporated in coronary artery bypass graft surgery have made the procedure safer and more effective, so patients who were previously candidates for heart transplants are now frequently revascularized. Hausmann et al. showed that, with the more comprehensive indication of myocardial revascularization in this scenario, patients [...] Ischemic Cardiomyopathy Ischemic heart disease is the most common cause, and at the same time, it is the main isolated risk factor that favors the increased incidence of heart failure in the world. Several improvements incorporated in coronary artery bypass graft surgery have made the procedure safer and more effective, so patients who were previously candidates for heart transplants are now frequently revascularized. Hausmann et al. showed that, with the more comprehensive indication of myocardial revascularization in this scenario, patients
- 17 August 2023
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 3 (1)
Surgical Treatment of Cardiomyopathy
Ischemic Cardiomyopathy Ischemic heart disease is the most common cause, and at the same time, it is the main isolated risk factor that favors the increased incidence of heart failure in the world. Several improvements incorporated in coronary artery bypass graft surgery have made the procedure safer and more effective, so patients who were previously candidates for heart transplants are now frequently revascularized. Hausmann et al. showed that, with the more comprehensive indication of myocardial revascularization in this scenario, patients [...] Ischemic Cardiomyopathy Ischemic heart disease is the most common cause, and at the same time, it is the main isolated risk factor that favors the increased incidence of heart failure in the world. Several improvements incorporated in coronary artery bypass graft surgery have made the procedure safer and more effective, so patients who were previously candidates for heart transplants are now frequently revascularized. Hausmann et al. showed that, with the more comprehensive indication of myocardial revascularization in this scenario, patients
- 29 June 2022
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 136-137
Biologic Left Ventricular Assist: A New Strategy for Patients with Advanced Heart Failure with Pulmonary Hypertension
Pulmonary arterial hypertension due to increased vascular resistance is a clinical condition that directly impacts the prognosis of patients with heart failure (HF), and it is considered one of the main contraindications to orthotopic heart transplantation. Although hemodynamic values vary in the literature, there is a consensus that pulmonary artery systolic pressure above 50 mmHg, transpulmonary gradient above 15 mmHg, and pulmonary vascular resistance above 3 Wood units, when unresponsive to vasodilators, contraindicate orthotopic transplantation. Therapeutic strategies to decrease or [...] Pulmonary arterial hypertension due to increased vascular resistance is a clinical condition that directly impacts the prognosis of patients with heart failure (HF), and it is considered one of the main contraindications to orthotopic heart transplantation. Although hemodynamic values vary in the literature, there is a consensus that pulmonary artery systolic pressure above 50 mmHg, transpulmonary gradient above 15 mmHg, and pulmonary vascular resistance above 3 Wood units, when unresponsive to vasodilators, contraindicate orthotopic transplantation. Therapeutic strategies to decrease or
- 29 June 2022
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 136-137
Biologic Left Ventricular Assist: A New Strategy for Patients with Advanced Heart Failure with Pulmonary Hypertension
Pulmonary arterial hypertension due to increased vascular resistance is a clinical condition that directly impacts the prognosis of patients with heart failure (HF), and it is considered one of the main contraindications to orthotopic heart transplantation. Although hemodynamic values vary in the literature, there is a consensus that pulmonary artery systolic pressure above 50 mmHg, transpulmonary gradient above 15 mmHg, and pulmonary vascular resistance above 3 Wood units, when unresponsive to vasodilators, contraindicate orthotopic transplantation. Therapeutic strategies to decrease or [...] Pulmonary arterial hypertension due to increased vascular resistance is a clinical condition that directly impacts the prognosis of patients with heart failure (HF), and it is considered one of the main contraindications to orthotopic heart transplantation. Although hemodynamic values vary in the literature, there is a consensus that pulmonary artery systolic pressure above 50 mmHg, transpulmonary gradient above 15 mmHg, and pulmonary vascular resistance above 3 Wood units, when unresponsive to vasodilators, contraindicate orthotopic transplantation. Therapeutic strategies to decrease or
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 67 (1) , 29-32
First case of extracorporeal membrane oxygenation in cardiorespiratory arrest in an emergency room in Brasil: a possible reality?
The extracorporeal membrane oxygenation (ECMO) is a procedure that has been used for a long time in reference centers worldwide. Its fundamental precept is to serve as a bridge to a definitive treatment in patients with severe, but potentially reversible, clinical conditions. Despite this, its use in cardiopulmonary arrest (ECPR) is still a matter of debate, especially when indicated in the emergency department. There is not yet a sufficient level of evidence to support its routine use. In Brasil, the procedure stopped being considered an experimental technique by the Federal Council of Medicine only in 2017. The objective of the present case is to share the pioneering spirit of a Brazilian reference center with ECPR in the emergency room and to discuss the future challenges of the ECMO technique.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 67 (1) , 29-32
Open AccessFirst case of extracorporeal membrane oxygenation in cardiorespiratory arrest in an emergency room in Brasil: a possible reality?
The extracorporeal membrane oxygenation (ECMO) is a procedure that has been used for a long time in reference centers worldwide. Its fundamental precept is to serve as a bridge to a definitive treatment in patients with severe, but potentially reversible, clinical conditions. Despite this, its use in cardiopulmonary arrest (ECPR) is still a matter of debate, especially when indicated in the emergency department. There is not yet a sufficient level of evidence to support its routine use. In Brasil, the procedure stopped being considered an experimental technique by the Federal Council of Medicine only in 2017. The objective of the present case is to share the pioneering spirit of a Brazilian reference center with ECPR in the emergency room and to discuss the future challenges of the ECMO technique.